On May 15, 2019 Pfizer Inc. (NYSE:PFE) reported that it will present data across its industry-leading oncology portfolio, covering multiple tumor types and mechanisms of action at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) in Chicago from May 31-June 4, 2019 (Press release, Pfizer, MAY 15, 2019, View Source [SID1234536356]). Data will highlight Pfizer’s cutting-edge approach, expertise in precision medicine and work in immunotherapy combinations, including company-sponsored and collaborative research studies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The data presented at this year’s ASCO (Free ASCO Whitepaper) showcase our continued commitment to follow the science, whether it’s expanding our approved medicines for breast and prostate cancers into new populations and lines of therapy, or exploring the important role of biomarkers and immunotherapy combinations," said Dany Habr, M.D., Chief Medical Officer, Pfizer Oncology. "We look forward to both sharing our exciting data in these and other tumor types, as well as connecting with our research partners to determine how we can continue to work collaboratively to bring transformative therapies to our cancer patients."
The research to be presented includes new insights on Pfizer’s marketed therapies, including IBRANCE (palbociclib), XTANDI (enzalutamide), TALZENNA (talazoparib), BOSULIF (bosutinib), INLYTA (axitinib) and BAVENCIO (avelumab), which represent Pfizer Oncology’s long-standing legacy of developing innovative therapies for patients in need, as well as its ongoing commitment to addressing the needs of cancer patients across gender, ethnicity and tumor type. For example, Pfizer will present real-world data on the use of IBRANCE for the treatment of men with metastatic breast cancer (MBC).
"At this year’s ASCO (Free ASCO Whitepaper), I am particularly excited that we’ll share data from new initiatives such as the oral presentation of talazoparib in breast cancer or other solid tumors. This builds on a productive year with the approval of four new oncology treatments, three biosimilars and three new indications, including one based on real-world evidence," said Chris Boshoff, M.D., Ph.D., Chief Development Officer, Oncology, Pfizer Global Product Development. "We are proud to have one of the broadest oncology portfolios in the industry, and a research philosophy that puts patients first, embraces new approaches and showcases innovative thinking."
Key Pfizer-sponsored, investigator-sponsored and collaborative research abstracts leveraging the depth of Pfizer’s scientific advances include:
A poster presentation on real-world evidence of male breast cancer patients treated with IBRANCE in combination with endocrine therapy (Abstract 1055).
An external investigator-sponsored oral presentation on a Phase 2 trial examining TALZENNA beyond BRCA, specifically as monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes (Investigator-sponsored abstract 3006).
Biomarker analyses from JAVELIN Renal 101 that studied BAVENCIO plus INLYTA vs. sunitinib in advanced renal cell carcinoma (aRCC) (Abstract 101).
An external collaborative research presentation on genomic markers of early progression on fulvestrant with or without IBRANCE for ER+ advanced breast cancer in the PALOMA-3 trial (Collaborative research abstract 1010).
Details for the Pfizer-sponsored, investigator-sponsored and collaborative research oral presentations are below:
Title/Abstract Number Date/Time (CDT) Location
(Abstract 101)
Biomarker Analyses from JAVELIN Renal 101: Avelumab + Axitinib (A + Ax) vs Sunitinib (S) in Advanced Renal Cell Carcinoma (aRCC)
Choueiri TK
Saturday, June 1
8:12 AM – 8:24 AM
Hall D1
(Abstract 1010)
Genomic Markers of Early Progression on Fulvestrant with or without Palbociclib for ER+ Advanced Breast Cancer in the PALOMA-3 Trial
O’Leary B
Saturday, June 1
3:12 PM – 3:24 PM
Hall D1
(Abstract 3006)
Talazoparib Beyond BRCA: A Phase II Trial of Talazoparib Monotherapy in BRCA1 and BRCA2 Wild-Type Patients with Advanced HER2-Negative Breast Cancer or Other Solid Tumors with a Mutation in Homologous Recombination (HR) Pathway Genes
Gruber J
Monday, June 3
10:00 AM – 10:12 AM
S406
(Abstract 5502)
Phase 2, Two-Group, Two-Stage Study of Avelumab in Patients (Pts) with Microsatellite Stable (MSS), Microsatellite Instable (MSI) and Polymerase Epsilon (POLE) Mutated Recurrent/Persistent Endometrial Cancer (EC)
Konstantinopoulos PA
Monday, June 3
1:39 PM – 1:51 PM
S406
(Abstract 1007)
A Randomized Phase II Study of Palbociclib plus Exemestane with GNRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer (KCSG-BR 15-10, NCT02592746)
Park YH
Tuesday, June 4
11:45 AM – 11:57 AM
Hall D1
Please see a complete list of Pfizer-sponsored abstracts featuring data on our broad pipeline of biologics and small molecules at View Source
Learn more about how developing new medicines and supporting people with cancer is personal for Pfizer Oncology at View Source
Please see full US Prescribing Information and Medication Guide for BAVENCIO (avelumab) available at View Source
Please see full Prescribing Information for INLYTA (axitinib) at www.Inlyta.com.
Please see full Prescribing Information for BOSULIF (bosutinib) at www.Bosulif.com.
Please see full Prescribing Information for IBRANCE (palbociclib) at www.Ibrance.com.
Please see full Prescribing Information for TALZENNA (talazoparib) at www.Talzenna.com.
Please see full Prescribing Information for XTANDI (enzalutamide) at www.Xtandi.com.